Q-linea AB (publ) (OMX:QLINEA) today announces that the company has applied for a unique New Technology Add-on Payment (NTAP) code for the US market.

 The Centers for Medicare & Medicaid Services (CMS) offers manufacturers the ability to apply for a NTAP code, providing additional payment to hospitals above the standard Medicare Severity Diagnosis-Related Group (MS-DRG) payment amount. A product’s NTAP designation lasts for no more than 3 years for a specific indication.
 
Stuart Gander, President & CEO of Q-linea Group, said: “By meeting the NTAP criteria, it is our expectation that the ASTar Gram-negative panel qualifies for this funding. This should support labs in offsetting extra costs to implement the test and thereby accelerate the timeline to bring the technology to patients who will benefit.”
 
The formal decision for funding will be announced in October 2024 for funding from January 2025.

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

Q-linea applies for a NTAP code for the US market

© Modular Finance, source Nordic Press Releases